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Background: Women who initiate antiretroviral therapy (ART) dur-
ing pregnancy are reported to have lower risk of preterm birth com-
pared with those who enter pregnancy care already receiving ART. We 
hypothesize this association can be largely attributed to selection bias.
Methods: We simulated a cohort of 1000 preconceptional, HIV-infected 
women, where half were randomly allocated to receive immediate ART 
and half to delay ART until their presentation for pregnancy care. Ges-
tational age at delivery was drawn from population data unrelated to 
randomization group (i.e., the true effect of delayed ART was null). Out-
comes of interest were preterm birth (<37 weeks), very preterm birth 
(<32 weeks), and extreme preterm birth (<28 weeks). We analyzed out-
comes in 2 ways: (1) a prospectively enrolled clinical trial, where all 
women were considered (the intent-to-treat (ITT) analysis); and (2) an 
observational study, where women who deliver before initiating ART 
were excluded (the naïve analysis). We explored the impact of later ART 
initiation and gestational age measurement error on our findings.
Results: Preconception ART initiation was not associated with preterm 
birth in ITT analyses. Risk ratios (RRs) for the effect of preconception 
ART initiation were RR = 1.10 (preterm), RR = 1.41 (very preterm), 
and RR = 5.01 (extreme preterm) in naïve analyses. Selection bias 
increased in the naïve analysis with advancing gestational age at ART 
initiation and with introduction of gestational age measurement error.
Conclusions: Analyses of preterm birth that compare a preconception 
exposure to one that occurs in pregnancy are at risk of selection bias. 
See video abstract at, http://links.lww.com/EDE/B313.
(Epidemiology 2018;29: 224–229)
Increasing availability of combination antiretroviral therapy (ART) has transformed the global human immunodeficiency 
virus (HIV) pandemic. Perhaps nowhere is this more evident than 
in the antenatal clinic, where lifelong ART is now the worldwide 
standard of pregnancy care for HIV-infected pregnant women.1 
As these programmatic successes have dramatically improved 
maternal health and reduced mother-to-child HIV transmission 
in many settings, new concerns have emerged regarding anti-
retroviral drug exposure and adverse birth outcomes, especially 
preterm birth (usually defined as birth before 37 weeks com-
pleted gestation) and its close correlate, low birthweight.2,3
Timing of ART initiation with respect to gestation is fre-
quently reported as a risk factor for preterm birth and low birth 
weight. Some observational studies suggest that ART initiated 
before conception (or very early in pregnancy) may cause a higher 
risk of preterm birth than ART started later in pregnancy. The Euro-
pean Collaborative Study and the Swiss Mother and Child HIV 
Cohort Study found that women who initiated ART preconception 
or in the first trimester had 2.17 (95% confidence interval [CI] = 
1.03, 4.58) times the odds of preterm birth compared with women 
who initiated in the second or third trimester.4 Similar results indi-
cating a higher risk with early initiation have since been reported 
in Brazil,5 Europe,6–8 Botswana,9 Nigeria,10 Tanzania,11 and the 
United States.3,12 A recent meta-analysis of studies before 2016 
found that women who initiated ART before conception were more 
likely to deliver preterm (RR = 1.20; 95% CI = 1.01, 1.44) or very 
preterm (RR = 1.53; 95% CI = 1.22, 1.92) compared with women 
initiating during pregnancy.13 In contrast, few studies reported a 
null effect of timing14,15 or an increased risk of preterm birth with 
the initiation of treatment later during pregnancy compared with 
preconception.16,17 All evidence to date is based on observational 
studies, and randomized evidence is not forthcoming.
The preconception ART would be associated with 
a higher risk of preterm birth seems at odds with biology. 
Untreated HIV infection is characterized by systemic inflam-
mation and immune activation and confers an increased risk 
of preterm birth.18 Although preterm birth is a complex syn-
drome with several causes, the most common phenotype is 
inflammatory,19 where local or systemic inflammation trigger 
labor prematurely. Control of viral replication with ART dra-
matically reduces inflammation and immune activation over 
time. Thus, preconception ART would be expected to reduce, 
not potentiate, the risk of preterm birth.
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We hypothesized that reports of an increased risk of 
preterm birth associated with preconception ART initiation 
largely arose from selection bias. In earlier studies, which have 
all been observational, women who experience a preterm birth 
before starting ART are systematically excluded from analy-
ses.13 Exclusion of these women may result in a falsely low-
ered risk of preterm birth among those women who remain, 
thus inflating the risk ratio for preterm birth when compared 
with those who initiate before conception. If women were 
randomized to timing of treatment and followed to delivery 
as in an intent-to-treat (ITT) analysis of a randomized trial, 
the randomization and ITT analysis would protect against this 
selection bias. We further hypothesized that the selection bias 
would be more pronounced in the following circumstances 
(1) settings where women initiate treatment later in gestation,
(2) settings where ultrasound dating is not routine and thus
gestational age measurements are imprecise, and (3) analyses
that define preterm birth with criteria earlier in gestation (e.g.,
<32, <28 weeks). Here, we use simulated data to explore and
quantify the extent of selection bias reasonably possible in the
effect of immediate versus delayed (during pregnancy) ART
initiation on preterm birth in HIV-infected women.
METHODS
Research in this topic area aims to answer the follow-
ing question: Should HIV-infected women who intend preg-
nancy in the near future start ART immediately or wait until 
they become pregnant? The specific interest is in whether such 
a strategy would result in a reduction in the risk of preterm 
birth. We are not interested in the effect of ART initiation on 
fecundability or on early pregnancy loss/miscarriage (although 
these questions are also interesting and potentially relevant). 
Toward this end, we simulated a cohort of 1,000 HIV-infected 
women recruited into a trial before conception (eCode; http://
links.lww.com/EDE/B282).20 A sample size of 1,000 was cho-
sen to be similar in size to earlier observational studies. Half 
of the cohort was randomized to immediate (preconception) 
ART and the other half was randomized to delay treatment 
initiation until pregnancy. Although under real-world condi-
tions, we would expect approximately 80% of participants to 
become pregnant within the first 6 months and more than 90% 
within 1 year,21 we assumed for purposes of this exercise that 
all women would become pregnant and carry their pregnancy 
to viability. The outcomes of interest were preterm birth, very 
preterm birth, and extreme preterm birth, which were defined 
as birth before 37, 32, and 28 completed gestational weeks, 
respectively.22 Two critical timing measures were necessary for 
this simulation: gestational age at ART start and gestational 
age at delivery. To simulate these dates, we drew from multi-
nomial distributions based on data from the Zambia Electronic 
Perinatal Registration System (ZEPRS) (Figure).23 ZEPRS 
includes 12,324 deliveries to HIV-infected women initiating 
ART in pregnancy or the early postpartum period between 
2006 and 2012. Dates of initiation of treatment and delivery 
 
were assigned in our simulated data without respect to random-
ized group such that the true causal effect of delayed ART is 
null, and the true risk ratio is therefore one.
In an ITT analysis, preterm birth rates were compared 
between those women randomized to immediate precon-
ception ART and those randomized to delayed ART during 
pregnancy. In an alternate naïve analysis mimicking the obser-
vational evidence base, all women randomized to immediate 
preconception ART were compared with the subset of women 
randomized to delayed ART during pregnancy whose deliv-
ery occurred after ART was initiated (i.e., women who deliv-
ered before ART start were excluded). Groups were compared 
using the risk ratio and 95% confidence interval, as estimated 
with a log-binomial model fit by maximum likelihood. An 
average of 200 simulations was taken for all estimates. We 
also calculated the confidence interval coverage proportion as 
the percentage of the 200 confidence intervals that contained 
the true parameter value (ideally 95%).
We then explored scenarios shifting the gestational age 
at ART initiation in the cohort from 1 to 10 weeks later than 
the mean of 26 weeks estimated gestational age observed in 
the Zambia registry data. Next, we introduced measurement 
error in gestational age dating to our original scenario by add-
ing a random error to estimated gestational age at birth from a 
uniform distribution ranging from −2 to 2 weeks and from −5 
to 5 weeks. Finally, for all sets of assumptions, we evaluated 
the effect of using definitions of preterm birth with criteria 
limits earlier in the gestation (<37, <34, <28 weeks). SAS ver-
sion 9.3 (SAS Institute, Cary, NC) was used for all analyses.
RESULTS
In the ITT analysis, 34.7% of women who started ART 
preconception had a preterm birth, 6.6% had a very preterm 
birth, and 1.5% had an extreme preterm birth, similar to 35.1% 
preterm, 6.7% very preterm, and 1.6% extremely preterm in 
those who initiated during pregnancy. As expected, preterm 
birth (RR = 0.99; 95% CI = 0.84, 1.17), very preterm birth 
(RR = 0.98; 95% CI = 0.61, 1.57), and extreme preterm birth 
(RR = 0.95; 95% CI = 0.32, 2.79) were not associated with 
starting ART preconception (Table 1).
In the naïve analysis, which excluded women who deliv-
ered before initiating ART, 34.7% of women on preconcep-
tion ART had a preterm birth compared with 31.7% in those 
who initiated during pregnancy. A large proportion (69.8%) 
of those who were excluded delivered preterm and removing 
them from this arm of the trial artificially lowered the propor-
tion among those who remained. Thus, in the naïve analysis, 
the risk of preterm birth in women on preconception ART was 
1.10 times the risk of preterm birth in women who initiated 
later during pregnancy (95% CI = 0.92, 1.32). This bias of 
the effect estimate was stronger under the definition of very 
preterm birth (RR = 1.41; 95% CI = 0.82, 2.42) and extreme 
preterm birth (RR = 5.01; 95% CI = 1.35, 18.54) comparing 
preconception initiation to initiation during pregnancy.
Shifting the estimated gestational age when women 
initiated treatment did not change the risk ratio for the asso-
ciation between preconception initiation and preterm birth in 
the ITT analysis, irrespective of the gestational age criterion 
used to define preterm birth (Table 2). However, in the naïve 
analysis, bias in the risk ratio increased as women initiated 
treatment later during pregnancy. The risk ratios for the effect 
of preconception initiation on preterm birth (RR = 1.54; 95% 
CI = 1.21, 1.97) and very preterm birth (RR = 3.74; 95% CI 
= 1.43, 9.78) were higher when women initiated treatment 10 
weeks later than the mean of 26 weeks observed in the Zam-
bia registry. The RR for extreme preterm birth also increased 
dramatically with later treatment initiation, so much so as to 
become unstable (RR > 50; Table 2). The risk ratio was inflated 
at later gestational ages because shifting the ART initiation to 
an average of 36 weeks practically eliminates the chance of a 
preterm birth among the postconception ART initiators, espe-
cially among those with an extreme preterm birth.
Finally, in the ITT analysis, adding measurement error 
to the gestational age dating at birth again did not change the 
association between preconception ART and preterm birth 
(Table 3). However, the percentage of preterm, very preterm, 
and extreme preterm birth increased overall when adding ±2 
and ±5 weeks random error. In the naïve analysis, risk of pre-
term birth was higher among women who started preconcep-
tion ART compared with later during pregnancy when adding 
FIGURE. Distributions of gestational 
age from the ZEPRS. ART indicates anti-
retroviral therapy.
TABLE 1. Average Percentage with a Preterm Birth and Very Preterm Birth by Timing of Treatment Initiation and Average RR 
with Average 95% CI in the Intent-to-treat Versus Naïve Analysisa












<37 weeks Preconception 174 (34.7) 0.99 (0.84, 1.17) 0.95 174 (34.7) 1.10 (0.92, 1.32) 0.85
During pregnancy 175 (35.1) 1 1 144 (31.7) 1 1
Excluded women - - - 31 (69.8) - -
<32 weeks Preconception 33 (6.6) 0.98 (0.61, 1.57) 0.97 33 (6.6) 1.41 (0.82, 2.42) 0.77
During pregnancy 34 (6.7) 1 21 (4.7) 1 1
Excluded women - - - 12 (27.3) - -
<28 weeks Preconception 8 (1.5) 0.95 (0.32, 2.79) 0.96 8 (1.5) 5.01 (1.35, 18.54) 0.89
During pregnancy 8 (1.6) 1 4 (0.8) 1 1
Excluded women - - - 4 (9.3) - -
aITT: preconception N = 502, during pregnancy 498; naïve analysis: preconception N = 502, during pregnancy N = 454, excluded N = 44.
ITT indicates intent-to-treat.
up to 2 weeks (RR = 1.11; 95% CI = 0.96, 1.31) and 5 weeks 
measurement error (RR = 1.12; 95% CI = 0.96, 1.32). The RR 
for the effect of preconception initiation on very preterm and 
extreme preterm birth also increased as more measurement 
error was added to gestational age dating. As measurement 
error increases, the standard errors decrease, owing to the 
increased number of preterm births.
DISCUSSION
This study provides a reasonable explanation for the 
counterintuitive finding i n e arlier r eports t hat p reconcep-
tional ART is associated with a higher risk of preterm birth 
than in those newly initiating ART in pregnancy. Our simu-
lation quantifies t he e xtent t o w hich e xclusion o f w omen 
who deliver before initiating ART selectively lowers the 
risk of preterm birth among those who remain. Because 
this selection applies only to women who initiate treatment 
during pregnancy, it makes continuation of preconceptional 
ART look worse by comparison. The effect of this selection 
bias is magnified as the average gestational age at treatment 
initiation advances, with increasingly severe definitions of 
preterm birth, and with increased measurement error in 
gestational age dating. Typically, when nondifferential mea-
surement error is introduced, it is expected to produce bias 
toward the null. However, under our naïve analysis with 
selection bias, increased measurement error increased the 
number of preterm births and the number who are excluded 
because they deliver before ART initiation.
Our results are compatible with earlier studies showing 
an elevated risk of preterm birth with preconception initiation. 
The magnitude of the association of preconception initiation 
with preterm birth was half that of the recent meta-analysis 
(pooled RR = 1.20; 95% CI = 1.01, 1.44).13 The meta-analysis 
also reported a higher association in low- and middle-income 
countries (pooled RR = 1.41; 95% CI = 1.22, 1.63) compared 
with high-income countries (pooled RR = 0.89; 95% CI = 0.54, 
1.47).13 These results are compatible with our theory that the 
bias will be higher in settings where women present to care 
later in gestation and where pregnancy dating relies on patient 
report of the last menstrual period rather than ultrasound biom-
etry. In addition, there was a higher RR for the effect of pre-
conception initiation on very preterm birth (pooled RR = 1.53; 
95% CI = 1.22, 1.92),13 which is similar to our results. When we 
used a criterion for preterm birth earlier in gestation, a greater 
proportion of preterm births in the cohort are systematically 
removed, and the RR is further inflated. To address selection 
bias, researchers can randomize women to ART, define expo-
sures prospectively, or use methods to address selection bias, 
such as inverse probability weighting.24
While an epidemiologist who has been sensitized to 
biases in observational studies might recognize this selec-
tion bias immediately, the wider community of health and 
medical scientists may not, as evidenced by publication of 
these articles in prestigious journals without discussion of 
this possible bias. We chose to explore this likely selection 
bias using simulation so that we could quantify the size of 
the bias using realistic input data, alternatively one could 
quantify the bias analytically. Our simulation shows the 
magnitude of bias under the null where there is no associa-
tion between ART initiation and preterm birth. However, it 
is possible that there is also some effect of ART initiation 
on preterm birth operating in addition to this selection bias. 
If there was a harmful effect of preconception ART initia-
tion on preterm birth, we would expect the magnitude of the 
TABLE 2. Average RR and Average 95% CI for the Association Between Preconception Initiation Versus Initiation During 
Pregnancy, Shifting Estimated Gestational Age at Anti-Retroviral Therapy Initiation














<37 Weeks <32 Weeks <28 Weeks
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
26 0.99 (0.84, 1.17) 1.10 (0.92, 1.32) 0.98 (0.61, 1.57) 1.41 (0.82, 2.42) 0.95 (0.32, 2.79) 5.01 (1.35, 18.54)
27 0.99 (0.84, 1.18) 1.12 (0.94, 1.35) 1.00 (0.62, 1.6) 1.49 (0.86, 2.6) 0.99 (0.33, 2.96) 3.66 (0.86, 15.54)
28 0.99 (0.84, 1.18) 1.15 (0.95, 1.38) 1.02 (0.64, 1.64) 1.63 (0.92, 2.88) 0.96 (0.32, 2.84) 5.11 (1.15, 22.81)
29 1.01 (0.85, 1.2) 1.19 (0.98, 1.44) 1.02 (0.64, 1.63) 1.76 (0.98, 3.18) 0.98 (0.36, 2.79) 18.79 (0.06, 16.3)
30 0.99 (0.84, 1.18) 1.20 (0.99, 1.46) 1.00 (0.62, 1.6) 1.81 (0.99, 3.32) 1.09 (0.38, 3.15) 53.74 (12.53, 230.54)
31 1.00 (0.84, 1.18) 1.25 (1.02, 1.53) 0.98 (0.61, 1.56) 2.01 (1.05, 3.84) 0.99 (0.34, 2.86) >50a
32 1.00 (0.84, 1.18) 1.29 (1.05, 1.59) 1.03 (0.64, 1.64) 2.33 (1.17, 4.63) 1.03 (0.36, 2.97) >50a
33 1.00 (0.84, 1.19) 1.34 (1.08, 1.66) 0.99 (0.62, 1.58) 2.40 (1.17, 4.92) 1.03 (0.36, 2.96) >50a
34 0.99 (0.83, 1.17) 1.37 (1.1, 1.71) 0.99 (0.62, 1.58) 2.81 (1.28, 6.18) 0.99 (0.34, 2.92) >50a
35 1.01 (0.85, 1.2) 1.47 (1.16, 1.85) 1.02 (0.64, 1.65) 3.23 (1.36, 7.67) 1.04 (0.35, 3.07) >50a
36 1.01 (0.85, 1.19) 1.54 (1.21, 1.97) 0.99 (0.62, 1.58) 3.74 (1.43, 9.78) 1.00 (0.34, 2.92) >50a
aSample sizes are too small to show stable estimates because the number of preterm pregnancies is practically eliminated.
RR indicates relative risk, CI confidence interval.
association to be larger than what is observed in our simula-
tion, essentially the composite of the effect and the bias. If 
there was a protective effect of preconception ART initiation 
on preterm birth, we would expect the RR to appear closer to 
the null. The association reported in the recent meta-analysis 
(pooled RR = 1.20; 95% CI = 1.01, 1.44) suggests that there 
may be a harmful effect of delayed ART operating in addi-
tion to the illustrated selection bias.13
In addition to the case of ART initiation timing and pre-
term birth, this selection bias will apply in all naïve analyses of 
time-related exposures with preterm birth outcomes. For exam-
ple, in studies looking at timing of prenatal care visits or doses 
of malaria prophylaxis as an exposure in relation to preterm 
birth outcomes.25,26 When using a time-dependent exposure, 
there will always be women who are excluded because they 
deliver prematurely, before they can receive the timed exposure 
later in pregnancy. Therefore, the risk of preterm birth with 
later exposure will be falsely lowered and earlier exposure 
will appear to have a higher risk or later exposure will appear 
protective. For example, women with more prenatal care visits 
will have a lower risk of preterm birth compared with those 
fewer visits because women who have already had a preterm 
birth in the later category will be excluded.26 Further, the bias 
will apply in all studies in which the exposure and outcome 
are both contingent on survival in time. For example, when 
looking at age of first childbirth and survival to age 90 years, 
women who do not survive to have later births cannot survive 
to age 90 years and therefore, selection bias is introduced.27
Finally, in naïve analyses of observational studies look-
ing at the association between ART initiation and subsequent 
outcomes, the timing of ART initiation is often defined retro-
spectively. Essentially, these studies are asking the question 
“What is the effect of having previously initiated ART at the 
time of pregnancy compared with initiating it now or shortly 
thereafter?” Because one cannot retrospectively initiate ART, 
the implications of this question are unclear. By reconceptual-
izing the study as a randomized controlled trial we are able 
to more clearly answer the question “Should I initiate ART 
before I become pregnant?,” which is far more relevant in 
terms of developing an intervention.
Our simulation uses data from a cohort of pregnant 
women in Zambia, where gestational age dating is not con-
firmed by ultrasound and is not always accurate. Although 
estimates from our simulated cohort depend on the accuracy 
of these parameters, we have illustrated how the selection bias 
would be further affected by changing parameters in our study 
including the accuracy of gestational age dating and average 
timing of treatment initiation. The selection bias described 
may exist in similar settings but the magnitude of the bias 
should be assessed using empirical data from different set-
tings and by reporting median gestational age at ART initia-
tion, which is rarely provided in current studies.
In addition, there may be confounding in naïve analyses 
of observational data that could also explain the association 
between timing of ART initiation and preterm birth. Confound-
ing is not considered in our simulation The selection bias in our 
TABLE 3. Average Percentage with a Preterm Birth and Very Preterm Birth by Timing of Treatment Initiation and the Average 
RR with Average 95% CI in the Intent-to-treat Versus Naïve Analysis, Adding Measurement Error




Error Category N (%)








<37 weeks ±2 weeks Preconception 186 (37.0) 0.99 (0.85, 1.17) 0.97 186 (36.0) 1.11 (0.96, 1.31) 0.81
During pregnancy 185 (37.2) 1 154 (34.0) 1
Excluded women - - 31 (69.9)
±5 weeks Preconception 211 (42.0) 1.00 (0.87, 1.16) 0.96 211 (42.0) 1.12 (0.96, 1.32) 0.70
During pregnancy 209 (41.9) 1 1 179 (39.4) 1 1
Excluded women - - - 30 (67.6) - -
<32 weeks ±2 weeks Preconception 38 (7.5) 0.99 (0.64, 1.54) 0.94 38 (7.5) 1.42 (0.86, 2.35) 0.73
During pregnancy 38 (7.6) 1 25 (5.5)
Excluded women - 13 (23.4)
±5 weeks Preconception 56 (11.1) 1.00 (0.70, 1.42) 0.95 56 (11.1) 1.42 (0.94, 2.13) 0.60
During pregnancy 56 (11.2) 1 1 42 (9.2) 1 1
Excluded women - - - 14 (32.0) -
<28 weeks ±2 weeks Preconception 9 (1.7) 0.96 (0.36, 2.58) 0.97 9 (1.7) 2.17 (0.79, 5.98) 0.81
During pregnancy 9 (1.8) 1 4 (1.0) 1
Excluded women - - 4 (25.0) -
±5 weeks Preconception 14 (2.8) 1.00 (0.47, 2.14) 0.94 14 (2.8) 2.17 (0.79, 5.98) 0.69
During pregnancy 14 (2.8) 1 8 (1.8) 1
Excluded women - - - 6 (12.7) - -
simulation is a result of conditioning on a collider (i.e., women 
who start ART late and deliver early are excluded).28 If we 
were able to measure and control variables that are causes of 
delivering before initiating ART, we could reduce the selection 
bias. Finally, our simulation assumes women become pregnant, 
enter antenatal care, and carry a pregnancy to viability. While 
it is possible that fecundity and miscarriage may be related to 
preconception initiation of ART, evidence is currently lacking 
to establish a clear association13 and only women who become 
pregnant and do not have a miscarriage can have a preterm 
birth. Presentation for antenatal care may also be related to 
timing of ART initiation and to preterm birth but the intention 
of our trial is to mimic a randomized trial in which women 
would have to present for care to be put on treatment.
We have illustrated that the apparent effect of preconcep-
tion ART initiation on preterm birth may be due to a selection 
bias in naïve analyses of observational studies. The selection 
bias increases with lower thresholds of prematurity, when 
women initiate treatment later in pregnancy, and with mea-
surement error in gestational age dating. The magnitude of 
the association in current studies suggests that there may be a 
slight although reduced effect of preconception ART initiation 
on preterm birth, or that the association could be explained by 
the selection bias given the characteristics of the study popula-
tions. In the absence of randomized evidence, it is critical that 
researchers report the median gestational age at ART initiation 
to assess the potential for this bias in their studies and/or apply 
analytic strategies for dealing with the selection bias.
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